论文部分内容阅读
目的：探讨醒脑静注射液在治疗重症颅脑损伤患者中抗高热和促醒作用的疗效以及对预后的影响。方法：按随机分组法将１４１例颅脑损伤患者〔格拉斯哥昏迷评分（ＧＣＳ）≤８分〕分为２组。Ａ组（治疗组）７０例，伤后或术后在常规治疗基础上加用醒脑静注射液；Ｂ组（对照组）７１例只用常规治疗，比较用药７２小时内２组间高热发生率的差异；将Ｂ组治疗７２小时后出现高热患者又随机分为Ｂ１和Ｂ２２组。Ｂ１组加用醒脑静注射液降温，Ｂ２组用冬眠药物降温，观察Ｂ１，Ｂ２组间的降温效果及不良反应；并按格拉斯哥预后评分（ＧＯＳ）对Ａ组、Ｂ组的１周内意识好转率及预后作比较。结果：Ａ组患者高热发生率（２５．７％）明显低于Ｂ组（５７．７％，Ｐ＜０．０１）；Ａ组患者１周内清醒率（５５．７％），显著高于Ｂ组（２５．４％，Ｐ＜０．０１）。Ｂ１组无不良反应发生，Ｂ２组有１１例发生不良反应（Ｐ＜０．０１）。Ａ组患者预后恢复良好及中度恢复的百分率（５１．４％和２４．３％）均明显高于Ｂ组（分别为２６．７％和１８．３％），Ｐ均＜０．０５；２组患者病死率（分别为１２．９％和１４．１％）无显著性差异。结论：醒脑静注射液在治疗重症颅脑损伤患者时，早期能有效控制高热发生率，并对?
Objective: To investigate the effect of xingnaojing injection in treating patients with severe craniocerebral injury on antipyretic and arousal effects and prognosis. Methods: One hundred and forty-one patients with craniocerebral injury (Glasgow coma score ≤8 points) were divided into two groups by randomization. A group (treatment group) 70 cases, after injury or postoperative routine treatment plus Xingnaojing injection; B group (control group) 71 cases only conventional treatment, compared 72 hours after treatment with fever between the two groups Rate of difference; the group B treatment after 72 hours of high fever patients were randomly divided into B1 and B22 group. Group B1 was treated with xingnaojing injection, while group B2 was cooled with hibernating drug. The cooling effect and adverse reactions between group B1 and group B2 were observed. One week’s awareness of group A and group B was evaluated by Glasgow’s prognostic score (GOS) Improvement rate and prognosis for comparison. Results: The incidence of hyperthermia in group A was significantly lower than that in group B (57.7%, P <0.01). The awakening rate in group A was significantly higher than that in group B (55.7%) Group B (25.4%, P <0.01). There were no adverse reactions in group B1, and 11 in group B2 occurred adverse reactions (P <0.01). The percentage of patients with good prognosis and moderate recovery in group A (51.4% and 24.3%) were significantly higher than those in group B (26.7% and 18.3% respectively) (P <0.05). There was no significant difference in the case fatality rates between the two groups (12.9% and 14.1%, respectively). Conclusion: Xingnaojing injection in the treatment of patients with severe craniocerebral injury, the early effective control of the incidence of high fever, and?